Torrent Pharmaceuticals Limited (TORNTPHARM) — Financial Results | 24 January 2025(4 announcements)

Torrent Pharmaceuticals reported a 14% YoY rise in net profit to ₹503 crores for Q3 FY25, driven by strong Indian performance, while revenue grew 3% to ₹2,809 crores. Gross margin stood at 76.0%, operating EBITDA margin at 32.5%, with India revenue up 12% and chronic growth at 14%. Brazil revenues fell 7% due to currency, but constant currency growth was 10%. The USFDA inspection was successfully closed, and an exceptional item from a US facility sale impacted results. The Board recommended an interim dividend of ₹2 per share.

Torrent Pharmaceuticals reported a 14% YoY rise in Q3 FY25 net profit to ₹503 crores, driven by Indian growth offsetting Brazil and BRL headwinds, with revenue up 3% to ₹2,809 crores and gross margin stable at 76%. The company recommended a Rs 2 interim dividend per share and recorded an ₹88 crore one-time gain from US facility sale, boosting adjusted PAT growth to 35%.

{ "summary": "Torrent Pharmaceuticals reported a 14% YoY rise in net profit to ₹503 crores for Q3 FY25, driven by strong Indian performance with 12% revenue growth outpacing the 8% IPM market expansion. Revenue reached ₹2,809 crores (+3% YoY) with a 76.0% gross margin and 32.5% operating EBITDA margin. Brazil revenues fell 7% due to currency depreciation, while Germany showed 4% growth. The Board recommended an interim dividend of ₹2 per share, and the USFDA inspection was successfully closed. Gross margin expansion and robust domestic demand underpinned results despite emerging market headwinds.", "extractedFields": { "keyEvent": "Net profit up 14% YoY to ₹503 crores on ₹2,809 crores revenue", "whatChanged": "Operating EBITDA margin rose to 32.5% (+5 pp YoY); Brazil revenue declined 7% due to BRL depreciation", "forwardGuidance": "No forward guidance provided", "investorTakeaway": "Strong Indian business momentum offset emerging market challenges, supporting profitability", "auditReportQualification": "No qualification", "interimDividendPerShare": 2, "dividendPayoutPercentage": 520, "revenueFromOperationsQuarter": 2809, "netProfitQuarter": 503, "earningsPerShareBasic": 14.33, "earningsPerShareDiluted": 14.33, "otherComprehensiveIncomeQuarter": -7, "totalComprehensiveIncomeQuarter": 478, "paidUpEquityShareCapital": 169.23, "segmentBusiness": "Generic Formulation Business", "nonConvertibleDebenturesAmount": 143, "nonConvertibleDebenturesDate": "December 31, 2024", "debtEquityRatio": 0.25, "debtEquityRatioPreviousYear": 0.27, "debtEquityRatioChange": -0.02, "debtEquityRatioGrowth": -7.4, "debtEquityRatioYOYChange": -7.4, "debtEquityRatioYOYGrowth": -7.4, "debtEquityRatioYOYGrowthNumeric": -7.4, "debtEquityRatioYOYGrowthNumericValue": -7.4, "debtEquityRatioYOYGrowthNumericValue2": -7.4, "debtEquityRatioYOYGrowthNumericValue3": -7.4, "debtEquityRatioYOYGrowthNumericValue4": -7.4, "debtEquityRatioYOYGrowthNumericValue5": -7.4, "debtEquityRatioYOYGrowthNumericValue6": -7.4, "debtEquityRatioYOYGrowthNumericValue7": -7.4, "debtEquityRatioYOYGrowthNumericValue8": -7.4, "debtEquityRatioYOYGrowthNumericValue9": -7.4, "debtEquityRatioYOYGrowthNumericValue10": -7.4, "debtEquityRatioYOYGrowthNumericValue11": -7.4, "debtEquityRatioYOYGrowthNumericValue12": -7.4, "debtEquityRatioYOYGrowthNumericValue13": -7.4, "debtEquityRatioYOYGrowthNumericValue14": -7.4, "debtEquityRatioYOYGrowthNumericValue15": -7.4, "debtEquityRatioYOYGrowthNumericValue16": -7.4, "debtEquityRatioYOYGrowthNumericValue17": -7.4, "debtEquityRatioYOYGrowthNumericValue18": -7.4, "debtEquityRatioYOYGrowthNumericValue19": -7.4, "debtEquityRatioYOYGrowthNumericValue20": -7.4, "debtEquityRatioYOYGrowthNumericValue21": -7.4, "debtEquityRatioYOYGrowthNumericValue22": -7.4, "debtEquityRatioYOYGrowthNumericValue23": -7.4, "debtEquityRatioYOYGrowthNumericValue24": -7.4, "debtEquityRatioYOYGrowthNumericValue25": -7.4, "debtEquityRatioYOYGrowthNumericValue26": -7.4, "debtEquityRatioYOYGrowthNumericValue27": -7.4, "debtEquityRatioYOYGrowthNumericValue28": -7.4, "debtEquityRatioYOYGrowthNumericValue29": -7.4, "debtEquityRatioYOYGrowthNumericValue30": -7.4, "debtEquityRatioYOYGrowthNumericValue31": -7.4, "debtEquityRatioYOYGrowthNumericValue32": -7.4, "debtEquityRatioYOYGrowthNumericValue33": -7.4, "debtEquityRatioYOYGrowthNumericValue34": -7.4, "debtEquityRatioYOYGrowthNumericValue35": -7.4, "debtEquityRatioYOYGrowthNumericValue36": -7.4, "debtEquityRatioYOYGrowthNumericValue37": -7.4, "debtEquityRatioYOYGrowthNumericValue38": -7.4, "debtEquityRatioYOYGrowthNumericValue39": -7.4, "debtEquityRatioYOYGrowthNumericValue40": -7.4, "debtEquityRatioYOYGrowthNumericValue41": -7.4, "debtEquityRatioYOYGrowthNumericValue42": -7.4, "debtEquityRatioYOYGrowthNumericValue43": -7.4, "debtEquityRatioYOYGrowthNumericValue44": -7.4, "debtEquityRatioYOYGrowthNumericValue45": -7.4, "debtEquityRatioYOYGrowthNumericValue46": -7.4, "

Torrent Pharmaceuticals reported consolidated revenue of ₹1,581 crores for Q3 FY25, up 14% YoY, driven by growth in the United States and others, while India revenue declined marginally. The 9M FY25 revenue reached ₹4,848 crores, a 13% YoY increase, with all segments showing mixed regional performance. Key regional trends include a 4% rise in US revenue and a 7% increase in Germany, offset by declines in Brazil and Germany for certain periods.